# EDGAR Filing Document

**Accession Number:** 0001815776
**File Stem:** 0001815776-26-000013
**Filing Date:** 2026-3
**Character Count:** 35951
**Document Hash:** 26613e648271abd0ecf0355de84cf2cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001815776-26-000013.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001815776-26-000013

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**EFFECTIVENESS DATE**: 20260324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LENZ Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001815776
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844867570
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294569
- **FILM NUMBER:** 26786674

**BUSINESS ADDRESS:**
- **STREET 1:** 201 LOMAS SANTA FE DRIVE, SUITE 300
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075
- **BUSINESS PHONE:** 858-925-7000

**MAIL ADDRESS:**
- **STREET 1:** 201 LOMAS SANTA FE DRIVE, SUITE 300
- **CITY:** SOLANA BEACH
- **STATE:** CA
- **ZIP:** 92075

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Graphite Bio, Inc.
- **DATE OF NAME CHANGE:** 20210312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Integral Medicines, Inc.
- **DATE OF NAME CHANGE:** 20200622

**As filed with the Securities and Exchange Commission on March 24, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***Under***

***The Securities Act of 1933***

**LENZ THERAPEUTICS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **84-4867570** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification Number) |

---

---

| |
|:---|
| **201 Lomas Santa Fe Drive, Suite 300**<br>**Solana Beach, California 92075** |
| (Address of Principal Executive Offices, including zip code) |

---

---

| |
|:---|
| **LENZ Therapeutics, Inc. 2024 Equity Incentive Plan**<br>**LENZ Therapeutics, Inc. 2024 Employee Stock Purchase Plan** |
| (Full title of the plan) |

---

---

| |
|:---|
| **Evert Schimmelpennink**<br>**Chief Executive Officer**<br>**201 Lomas Santa Fe Drive, Suite 300**<br>**Solana Beach, California 92075** <br>**(858) 925-7000** |
| (Name, address and telephone number, including area code, of agent for service) |

---

*Copies to:*

**Dan Koeppen**<br>**Jennifer Fang**<br>**Robert L. Wernli, Jr.**<br>**Ben Capps**<br>**Wilson Sonsini Goodrich & Rosati, P.C.**<br>**12235 El Camino Real**<br>**San Diego, California 92130**<br>**(858) 350-2300**<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer  | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company  | ☒ |
| | | Emerging growth company  | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

**REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E**

This Registration Statement on Form S-8 (the "Registration Statement") is being filed to register an additional 1,567,239 shares of common stock of LENZ Therapeutics, Inc. (the "Registrant") reserved for issuance pursuant to future awards under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") as a result of the annual evergreen increase under the 2024 Plan and 313,447 shares of common stock of the Registrant reserved for issuance pursuant to future awards under the 2024 Employee Stock Purchase Plan (the "2024 ESPP") as a result of the annual evergreen increase under the 2024 ESPP.

These additional shares of common stock are securities of the same class as other securities for which previous Registration Statements on Form S-8 were filed by the Registrant with the Securities and Exchange Commission (the "SEC") on <u>[May 21, 2024](https://www.sec.gov/Archives/edgar/data/1815776/000162828024024451/lenz-sx8.htm)</u> (File No. 333-279572) and <u>[March 19, 2025](https://www.sec.gov/Archives/edgar/data/1815776/000162828025013856/lenz-sx82025.htm)</u> (File No. 333-285926) (the "Previous Registration Statements"). In accordance with General Instruction E of Form S-8, the contents of the Previous Registration Statements, including periodic reports filed after the Previous Registration Statements to maintain current information about the Registrant, are incorporated by reference into this Registration Statement.

**PART II**

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the SEC:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Registrant's Annual Report on <u>[Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001815776/000181577626000011/lenz-20251231.htm)</u> (File No. 001-40532) for the fiscal year ended December 31, 2025 filed with the SEC on March 24, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)All other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), since the end of the fiscal year covered by the Registrant's Annual Report referred to in (1) above, only to the extent that the items therein are specifically stated to be "filed" rather than "furnished" for the purposes of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The description of the Registrant's Common Stock contained in <u>[Exhibit 4.4](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000019/exhibit44descriptionofther.htm)</u> to the Company's Annual Report on Form 10-K filed with the Commission on March 19, 2025, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 5. Interests of Named Experts and Counsel.**

The validity of the issuance of the shares of the Registrant's common stock offered hereby has been passed upon by Wilson Sonsini Goodrich & Rosati, Professional Corporation ("WSGR"). Certain members of, and investment

------

partnerships comprised of members of, and persons associated with, WSGR, directly or indirectly, own less than 0.1% of the outstanding shares of the Registrant's common stock.

**Item 8. Exhibits.**

The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

**EXHIBIT INDEX** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br>**Number** | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit**<br>**Number** |<br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation, as amended, of LENZ Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1815776/000162828024012633/exhibit31-super8xk.htm)</u> | 8-K | 001-40532 | 3.1 | March 22, 2024 |
| 4.2 | <u>[Amended and Restated Bylaws of LENZ Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1815776/000119312521204869/d169897dex32.htm)</u> | 8-K | 001-40532 | 3.2 | June 30, 2021 |
| 4.3 | <u>[Specimen Common Stock Certificate.](https://www.sec.gov/Archives/edgar/data/1815776/000119312521189004/d132211dex41.htm)</u> | S-1 | 333-256838 | 4.1 | June 11, 2021 |
| 4.4 | <u>[2024 Equity Incentive Plan and related form agreements.](https://www.sec.gov/Archives/edgar/data/1815776/000162828024012633/exhibit109-super8xk.htm)</u> | 8-K | 001-40532 | 10.9 | March 22, 2024 |
| 4.5 | <u>[2024 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1815776/000162828024012633/exhibit1010-super8xk.htm)</u> | 8-K | 001-40532 | 10.10 | March 22, 2024 |
| 5.1 | <u>[Opinion of Wilson Sonsini Goodrich & Rosati, P.C.](exhibit51-sx82026.htm)</u> |  |  |  |  |
| 23.1 | <u>[Consent of Independent Registered Accounting Firm](exhibit231-sx82026.htm)</u> |  |  |  |  |
| 23.2 | <u>[Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto).](exhibit51-sx82026.htm)</u> |  |  |  |  |
| 24.1 | <u>[Power of Attorney (included on the signature page hereto).](#ifa1be382d77d49829c213f598572ddc3_13)</u> |  |  |  |  |
| 107 | <u>[Filing Fee Table](exfilingfees.htm)</u> |  |  |  |  |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Solana Beach, State of California, on March 24, 2026.

---

| | |
|:---|:---|
| **LENZ THERAPEUTICS, INC.** | **LENZ THERAPEUTICS, INC.** |
| By: | /s/ Evert Schimmelpennink |
|  | Evert Schimmelpennink |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Evert Schimmelpennink and Daniel Chevallard, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Evert Schimmelpennink | Chief Executive Officer, President and Director | March 24, 2026 |
| Evert Schimmelpennink | (Principal Executive Officer) |  |
| /s/ Daniel Chevallard | Chief Financial Officer | March 24, 2026 |
| Daniel Chevallard | (Principal Financial and Accounting Officer) |  |
| /s/ Jeff George | Director | March 24, 2026 |
| Jeff George |  |  |
| /s/ Frederic Guerard | Director | March 24, 2026 |
| Frederic Guerard |  |  |
| /s/ James McCollum | Director | March 24, 2026 |
| James McCollum |  |  |
| /s/ Zach Scheiner | Director | March 24, 2026 |
| Zach Scheiner |  |  |
| /s/ Shelley Thunen | Director | March 24, 2026 |
| Shelley Thunen |  |  |
| /s/ Kimberlee C. Drapkin | Director | March 24, 2026 |
| Kimberlee C. Drapkin |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-8**

(Form Type)

**LENZ Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Table 1 – Newly Registered Securities**

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, par value $0.00001 per share, reserved for issuance under the Registrant's 2024 Equity Incentive Plan | Rule 457(c) and Rule 457(h) | 1567239<sup>(2)</sup> | $11.55<sup>(4)</sup> | $18101611 | 0.00013810 | $2500.00 |
| Equity | Common Stock, par value $0.00001 per share, reserved for issuance under the Registrant's 2024 Employee Stock Purchase Plan | Rule 457(c) and Rule 457(h) | 313447<sup>(3)</sup> | $9.82<sup>(5)</sup> | $3078050 | 0.00013810 | $426.00 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $21179661 |  | $2926.00 |
| **Total Fee Offsets**<sup>(6)</sup> | **Total Fee Offsets**<sup>(6)</sup> | **Total Fee Offsets**<sup>(6)</sup> | **Total Fee Offsets**<sup>(6)</sup> |  |  |  | – |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $2926.00 |
| (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. | (1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") shall also cover any additional shares of the Registrant's Common Stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "2024 Plan") or the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock. |
| (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. | (2) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 Plan as a result of the annual evergreen increase under the 2024 Plan. |
| (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. | (3) Represents an automatic increase in the number of shares of Common Stock reserved for issuance pursuant to future awards under the 2024 ESPP as a result of the annual evergreen increase under the 2024 ESPP. |
| (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). | (4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $11.55, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Global Select Market ("Nasdaq") on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC")). |
| (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. | (5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $9.82, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 19, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the Common Stock on (i) the first trading day of the offering period or (ii) the exercise date. |
| (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. | (6) The Registrant does not have any fee offsets. |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![wilsonsonsinilogo.jpg](wilsonsonsinilogo.jpg) | Wilson Sonsini Goodrich & Rosati<br>Professional Corporation<br>12235 El Camino Real<br>San Diego, California 92130<br>o: 858.350.2300<br>f: 866.974.7329 |

---

March 24, 2026

LENZ Therapeutics, Inc.

201 Lomas Santa Fe Dr., Suite 300

Solana Beach, California 92075

**Re: <u>Registration Statement on Form S-8</u>**

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by LENZ Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), with the Securities and Exchange Commission on or about the date hereof, in connection with the registration under the Securities Act of 1933, as amended, of an aggregate of 1,880,686 shares (the "<u>Shares</u>") of the Company's common stock, par value $0.00001 per share ("<u>Common Stock</u>"), consisting of (i) 1,567,239 shares of Common Stock reserved for future issuance under the Company's 2024 Equity Incentive Plan and (ii) 313,447 shares of Common Stock reserved for issuance under the Company's 2024 Employee Stock Purchase Plan. As the Company's legal counsel, we have reviewed the actions proposed to be taken by the Company in connection with the issuance and sale of the Shares to be issued under such plans (which plans are referred to herein as the "<u>Plans</u>").

It is our opinion that the Shares, when issued and sold in the manner referred to in the Plans and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement, and further consent to the use of our name wherever appearing in the Registration Statement and any amendments thereto.

---

| |
|:---|
| Very truly yours, |
| WILSON SONSINI GOODRICH & ROSATI, |
| Professional Corporation |
| /s/ Wilson Sonsini Goodrich & Rosati, P.C. |

---

AUSTIN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BEIJING&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BOSTON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BRUSSELS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HONG KONG&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LONDON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOS ANGELES&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEW YORK&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PALO ALTO

SAN DIEGO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAN FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEATTLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHANGHAI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WASHINGTON, DC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WILMINGTON, DE

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan of LENZ Therapeutics, Inc. of our report dated March 24, 2026, with respect to the consolidated financial statements of LENZ Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

March 24, 2026

<br>